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Aim: To evaluate changes in liver histology in patients with human immunodeﬁciency
virus/hepatitis C virus coinfection non-responders to a suboptimal Interferon + Ribavirine
regimen.
Materials  and methods: We  investigated 49 patients with two sequential liver biopsies: 18 were
non-responders to Interferon + Ribavirine treatment (Group hepatitis C virus Rx) adminis-
tered  after the 1st liver biopsy who underwent a 2nd liver biopsy after a median period of
3.92 year and 31 were patients who remained untreated for hepatitis C virus disease (Group
hepatitis  C virus untreated) after the 1st liver biopsy because of refusal and underwent a
2nd liver biopsy after a median period of 5.05-years. Most patients in both groups were
under  highly active antiretroviral therapy. At the time of 1st liver biopsy similar degrees of
necro-inﬂammation, ﬁbrosis and steatosis were observed in both groups. Changes in liver
lesions  between 1st and 2nd liver biopsys were adjusted for different intervals between liver
biopsys by a mathematic formula.
Results: Liver ﬁbrosis did not change in 88.9% of patients in Group hepatitis C virus Rx and
in  77.4% in Group hepatitis C virus untreated. A marked deterioration in liver ﬁbrosis wasobserved  in 5 (16%) patients in Group hepatitis C virus untreated and in none in Group hep-
atitis  C virus treated. Necro-inﬂammation and steatosis remained substantially unchanged
in  both groups.
Conclusion: Liver histology remained substantially unchanged in human immunodeﬁciency
virus/hepatitis C virus patients non-responder to anti-hepatitis C virus therapy over 4 years
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observation, suggesting an effective anti-hepatitis C virus early treatment for all hepatitis
C virus/human immunodeﬁciency virus coinfected patients who can reasonably tolerate
therapy.
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ne-third of patients carrying humanimmunodeﬁciency virus
HIV) have a concomitant hepatitis C virus (HCV) infection1–3
ssociated with severe liver ﬁbrosis4–6 and unfavorable
utcome.3,5–12 More  recently, the results of some studies sug-
est  that highly active antiretroviral therapy (HAART), by
avoring  the re-establishment of the immune-control, may
nduce  a more  favorable outcome of HCV related chronic
epatitis.11,3,13–15 Indeed, the methods used to evaluate the
rogression of liver ﬁbrosis in these studies are somewhat
uestionable, mostly because they are based on the observa-
ion  of a single liver biopsy (LB).
We may  contribute to this point by analyzing the data from
9  patients with HCV related chronic hepatitis who had under-
one  two sequential LBs, 18 patients with HIV/HCV coinfection
on-responders to an anti-HCV treatment and 31 patients
ith  HIV/HCV coinfection naïve for anti-HCV treatment. The
urpose  of the present study was  to evaluate whether sub-
ptimal  anti-HCV treatment that did not achieve sustained
irological response (SVR) inﬂuenced the progression of liver
brosis,  steatosis and necroinﬂammation between 1st and
nd  LB.
aterials  and  methods
ut of 440 HIV infected patients with chronic hepatitis C
ho  underwent liver biopsy from 1995 to 2007 we selected
9  patients with chronic hepatitis C who had undergone two
equential  LBs at an interval of at least 2 years.
Of these 49 HIV/HCV coinfected patients with chronic hep-
titis,  18 were  non-responders to treatment with Interferon
INF)  or INF plus Ribavirine after the 1st LB (Group HCV Rx);
ight  had HCV genotype 1 and 10 had HCV genotype 3. In
elation  to the period of time they were  investigated, nine
atients  in this group received standard INF 2a/2b 6 MU TIW,
ssociated  with Ribavirine 800–1000 mg  daily in four patients,
nd  nine Peg-INF 2a/2b one injection weekly, associated
ith Ribavirine 800–1000 mg  daily in seven patients. Fifteen
83.4%)  of these 18 patients were under HAART during the
tudy  (Table 1). All patients discontinued treatment after 3–4
onths  due to lack of response according to current interna-
ional  guidelines. These 18 patients underwent a 2nd LB to
ssess  possible changes in liver histology at the time (median
.05  years) they were  re-evaluated for re-treatment.
The remaining 31 patients with HIV/HCV coinfection
nd chronic hepatitis declined treatment for HCV infection
© 2013 Publishedfter  the 1st LB (Group HCV untreated) and were followed
s  well. Patients in this group underwent a 2nd LB for a new
ssessment of liver histology at the time (median 3.9 years)
hey  accepted to be re-evaluated for anti-HCV treatment.Twenty-four (77.4%) patients in this group received HAART
throughout the study (Table 1).
Patients were enrolled at the Clinic of Infectious Diseases of
the  San Raffaele Scientiﬁc Institute in Milan and investigated
in  cooperation with the Clinic of Infectious Diseases of the
Second  University of Naples. The procedures followed in this
study  were in accordance with the ethical standards of the
responsible  committee on human experimentation and with
the  Helsinki Declaration of 1975, as revised in 1983, and each
patient  signed an informed consent before each LB.
For  patients in both groups, the data recorded at the base-
line  (time of 1st LB) and at the time of 2nd LB included risk
factors  for acquiring HIV and HCV infection, presumed time
of  HIV and HCV infection, liver function tests, CD4+ and CD8+
counts,  HCV-genotype, HIV and HCV viral loads, and routine
tests.  The patients were observed at a three-month interval
with  physical examination and laboratory tests exploring liver
and kidney functions, blood cell count, CD4+ cell count, HIV
and  HCV viral loads.
Excluded  from this study were patients who  had been
treated with -INF or Peg-INF, alone or in combination with
Ribavirin  before the 1st LB, those with a history of alcohol
abuse  (>40 g/day for males and >30 g/day for females for at
least  5 years), those with HBsAg positive or autoimmune hep-
atitis,  and those with genetic disorders possibly inducing liver
disease.
Liver  histology
LB was performed percutaneously under US guidance; spec-
imens  were  ﬁxed in formalin, embedded in parafﬁn and
stained  with hematoxylin–eosin and Masson’s trichrome
stains. The histological data were analyzed by a pathologist
who  was  unaware of the clinical and laboratory data using
Ishak’s  scoring system for HAI and ﬁbrosis16 and a home made
scoring  system for steatosis he had been using for decades
(score  1 = 1–10% of hepatocytes with fatty deposition, score
2  = 11–30%; score 3 = 31–60%; score 4 ≥ 60%).
To compare the two groups of patients for changes in ﬁbro-
sis,  necro-inﬂammation and steatosis, avoiding the bias due
to  the different interval between LBs, a time-adjusted histo-
logical  difference (TAHD) was calculated for each histological
lesion  and in each single LB:
TAHD = score at the 2nd LB − score at the 1st LB
Interval between LBs
× 100
A negative TAHD indicated an improvement and a positive
TAHD  indicated deterioration.
For  an easier reading of the data, the TAHD value was
converted into Arbitrary Units, named Improvement Progres-
lsevier Editora Ltda.
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Unit  (DPU) for positive TAHD, where one Unit represents the
standard  difference of one degree of a histological lesion
in  the four years median interval between 2nd and 1st LB:
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Table 1 – Comparison of demographic, epidemiological and immuno-virological data at the time of 1st and 2nd liver
biopsy (LB) between Group HCV Rx and Group HCV untreated.
Group HCV Rx
18  cases
Group HCV untreated
31 cases
Signiﬁcance  level
Age, years 31.5  (28–37) 36  (31–41) <0.05
Males,  n (%) 10  (55.6) 23 (74.2) n.s.
IVDA, n (%) 17 (94.5) 26 (83.9) n.s.
With genotype 1, n (%) 8 (44.4) 12 (38.7) n.s.
With genotype 2, n (%) 0 2 (6.5%) n.s.
With genotype 3, n (%) 10 (55.6) 16 (51.6) n.s.
With genotype 4, n (%) 0 1 (3.2%) n.s.
Nadir of CD4, median (IQR) 265 (212–419) 230 (158–317) n.s.
Interval between LBs, years, median (IQR) 5.05 (4.18–6.98) 3.92 (2.33–5.09) <0.05
At the time of the 1st liver biopsy
HIV-RNA  cps/mL, median (IQR) 4000 (210–17000) 79 (79–4900) <0.02
CD4 cell/mmc, median (IQR) 626.5 (357–833) 459 (338–682) n.s.
ALT IU/L, n.v. = 15–35, median (IQR) 107 (82–307) 106 (69–158) n.s.
HCV RNA IU/L, median (IQR) 1126 × 103 (864–2500) 1260 × 103 (303–2380) n.s.
HAART at the 1st LB, n (%) 5 (27.8) 11 (35.5) n.s.
PI + NRT 0 3 (9.7)
NRT  + NNRT 10 (55.6) 9 (29)
NRT  3 (16.7) 8 (32.3)
Untreated
At  the time of the 2nd liver biopsy
HIV-RNA  cps/mL, median (IQR) 5396.5 (49–22788) 60.5 (49–1300) n.s.
CD4 cell/mmc, median (IQR) 674.5 (323–856) 547 (388–718) n.s.
ALT IU/L, n.v. = 15–35 112.5 (55–183) 95 (72–184) n.s.
HCV RNA IU/L, median (IQR) 793 × 103 (449–1130) 539 × 103 (95–820) n.s.
HAART at the 2nd LB, n (%) n.s.
PI + NRT 6 (33.4) 10 (32.3)
PI + NRT + NNRT 0 4 (12.9)
PI  1 (5.6) 0
NRT  + NNRT 2 (11.2) 5 (16.1)
NRT  3 (16.7) 
Untreated  7 (38.9) 
one Progression Unit (IPU or DPU) = one degree difference/four
years × 100 = 25 TAHD points. On the basis of this formula,
we  considered as improved all patients with a negative TADH
equivalent  to two or more  IPUs: an improvement of 2–6 IPUs
was  considered as moderate and an improvement of more
than  6 IPUs as marked. Conversely, all patients with a posi-
tive  TAHD equivalent to two or more  DPUs were considered
to  have deteriorated: a deterioration of 2–6 DPUs was  consid-
ered  as moderate and a deterioration of more  than six DPUs as
marked. The histological lesions were considered unchanged
when  variations in the degree of necro-inﬂammation, ﬁbro-
sis  or steatosis between the 2nd and 1st LB were minimal (<2
IPUs,  or <2 DPUs) or absent.
Laboratory  tests
Antibody to HCV was  determined by a 3rd generation commer-
cial  immunoenzymatic assay. HCV RNA was  determined in
plasma samples by a qualitative retro-transcriptase PCR with
primers  for 5′ non-coding region of the viral genome, using a
commercial kit with the lowest detection limit of 200 copies. In
HCV-RNA positive cases, HCV RNA was  assessed using quan-
titative  retro-transcriptase PCR (HCV-Amplicor Monitor 2.0;
Roche  Molecular System, Branchburg, NJ, USA), which shows
the  lowest detection limit of 600 IU/mL.5 (16.1)
7 (22.6)
HCV  genotyping was performed by a line-probe assay
(INNO-LIPA HCV-II; Innogenetics, Zwijndrecht, Belgium).
Antibodies to HIV-1 and 2 were determined by commercial
ELISA and positive results were conﬁrmed by Western blot,
which  identiﬁes antibodies to the HIV-1 and HIV-2 strains.
HIV  viral load was  assessed using the Amplicor HIV Moni-
tor  1 test (Roche Molecular Systems Inc., Branchburg, NJ, USA)
with  the lowest detection limit of 400 copies/mL.
HBsAg,  anti-HBs and total anti-HBc were  tested using
commercial immunoenzymatic assays. Lymphocyte sub-
sets  (CD4+, CD8+) were evaluated by ﬂow cytoﬂuorimetry
using monoclonal antibodies and a ﬂuorescence-activated
cell sorter scan (Becton Dickinson, Mountain View, USA).
Liver  function tests were carried out according to routine
methods.
Statistical  analysis
The analyses were  performed using SAS software (version 8.2;
SAS Institute, Cary, NC, USA). All tests of signiﬁcance were
2-sided,  and p < 0.05 was  considered statistically signiﬁcant.
Some  continuous parameters were  stratiﬁed according to their
median values and then used and compared as categorical
variables. Associations between discrete variables were  tested
by  2 or Fisher’s exact test, as appropriate.
 2 0 1 4;1 8(2):164–169  167
R
A
w
w
g
w
t
i
r
t
s
r
p
t
I
r
e
l
s
s
t
i
p
s
t
b
a
d
i
t
r
t
t
i
n
i
i
D
A
b
a
w
i
n
m
c
s
t
S
c
t
Table 2 – Scores of liver lesions (ﬁbrosis,
necro-inﬂammation (HAI) and steatosis) in the 1st and
2nd  liver biopsy (LB) in Group HCV Rx and Group HCV
untreated.
Group HCV Rx
18  cases
Group HCV
untreated
31  cases
Degree of ﬁbrosis
1st  LB, n (%)
0  1 (5.6) 0
1 7 (38.9) 16 (51.6)
2 3 (16.7) 8 (25.8)
3 4 (22.3) 1 (3.2)
4 3 (16.7) 1 (3.2)
5 0 3 (9.7)
6 0 2 (6.5)
2nd LB, n (%)
0  0 1 (3.2)
1 4 (22.3) 10 (32.3)
2 10 (55.6) 5 (16.1)
3 2 (11.2) 3 (9.7)
4 2 (11.2) 1 (3.2)
5 0 5 (16.1)
6 0 6 (19.4)
Degree of necro-inﬂammation
1st  LB, n (%)
0  0 2 (6.5)
1–3 12 (66.7) 13 (41.9)
4–8 4 (22.3) 12 (38.7)
9–12 0 1 (3.2)
13–18 2 (11.2) 3 (9.7)
2nd LB, n (%)
0  0 4 (12.9)
1–3 8 (44.5) 12 (38.7)
4–8 9 (50) 12 (38.7)
9–12 1 (5.6) 3 (9.7)
13–18 0 0
Degree of steatosis
1st  LB, n (%)
0  6 (33.4) 7 (22.6)
1 4 (22.3) 11 (35.5)
2 0 1 (3.2)
3 5 (27.8) 5 (16.1)
4 3 (16.7) 7 (19.4)
2nd LB, n (%)
0  7 (38.9) 10 (32.3)
1 7 (38.9) 9 (29)
2 0 0b r a z j i n f e c t d i s .
esults
t the time of the 1st LB patients in Group HCV Rx compared
ith  those in Group HCV untreated were younger (p < 0.05) and
ith  higher HIV viral load (p < 0.02) (Table 1). No other demo-
raphic,  epidemiological and immuno-virological difference
as  found between these two groups, neither at the time of
he  1st nor at the 2nd LB. Also the HAART regimen was  similar
n  these two groups (Table 1).
The raw histological scores observed in both groups are
eported  in Table 2 for an analytical evaluation, whereas
he  differences in necro-inﬂammation, ﬁbrosis and steato-
is  are presented as IPU and DPU in Table 3. Liver ﬁbrosis
emained substantially unchanged in 16 (88.9%) of the 18
atients  in Group HCV Rx, whereas a moderate deteriora-
ion  was  observed only in the remaining two (11.1%) (Table 3).
nstead,  of the 31 patients in Group HCV untreated, 24 (77.4%)
emained  substantially unchanged, two (6.5%) showed a mod-
rate  deterioration and ﬁve (16.1%) a marked deterioration in
iver ﬁbrosis (Table 3). These differences are not statistically
igniﬁcant, but the data are of clinical relevance since all the
even  patients who  deteriorated in Group HCV untreated had
he  minimal score of ﬁbrosis (score 1) at the ﬁrst LB, whereas
n  the 2nd LB, 3.6 years later (median value in these seven
atients), one patient progressed to score 3, another one to
core  4 and ﬁve to liver cirrhosis (two with score 5 and three
o  score 6).
Changes in necro-inﬂammation scores were  quite frequent
ut  similar in both groups (Table 3).
Changes in liver steatosis were  infrequent in both groups
nd  differences were not statistically signiﬁcant (Table 3).
In  both groups no association was  found between the
egree  of liver ﬁbrosis, necro-inﬂammation or liver steatosis
n  the 1st LB and a peculiar progression of these lesions in
he  2nd LB. Nevertheless, the data regarding liver ﬁbrosis are
eported  in Table 4, because of the relevance of this lesion on
he  course of chronic hepatitis and of the contrasting data on
he possibility to predict the progression to ﬁbrosis reported
n  literature.6,20,21,23–26 Table 4 shows, in terms of IPU or DPU,
o  correlation between the degrees of liver ﬁbrosis, necro-
nﬂammation and steatosis observed in the 1st LB and changes
n  liver ﬁbrosis found in the 2nd LB.
iscussion
pparently, non-effective anti-HCV treatment was  of some
eneﬁt  to our HIV/HCV coinfected patients with chronic hep-
titis.  In fact, no substantial deterioration in liver histology
as  observed after a median observation period of 5 years
n  18 non-responder patients to anti-HCV treatment, whereas
early  a quarter of the untreated patients progressed from the
inimal  degree of ﬁbrosis to moderate ﬁbrosis (6.5%) or to liver
irrhosis (16.1%) in four years. Lack of progression to a more
evere  liver ﬁbrosis was  also reported by Chung et al. in one-
hird  of 66 HIV/HCV coinfected patients who did not achieve
17VR  following anti-HCV treatment.
Independent predictors of ﬁbrosis progression in HIV/HCV
oinfection have been suggested, such as an old age at the
ime  of HCV infection, alcohol intake, and the entity of the3 1 (38.9) 4 (12.9)
4 3 (16.7) 8 (25.8)
necro-inﬂammatory lesions.18 However, due to the different
structure of published studies it is difﬁcult to reach a deﬁni-
tive  conclusion on this point. The HIV/HCV confected patients
in  the present investigation did not show such cofactors for
ﬁbrosis  progression since they had acquired HCV infection
at  a young age, most of them showed a low score of necro-
inﬂammation and none of them admitted a history of alcohol
abuse.  Moreover, most of them received an optimized HAART
regimen.
Some  authors found HCV-genotype 3 associated with liver
steatosis  in HIV/HCV coinfected patients,19–24 an association
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Table 3 – Histological changes between the 1st and 2nd liver biopsy (LB) in Group HCV Rx and Group HCV untreated,
expressed as Improvement Progression Unit (IPU) or Deterioration Progression Unit (DPU) for liver ﬁbrosis,
necro-inﬂammation (HAI) and steatosis.
Fibrosis HAI Steatosis
Group HCV Rx
18 cases
n  (%)
Group  HCV
untreated
31  cases
n  (%)
Group HCV Rx
18 cases
n (%)
Group  HCV
untreated
31  cases
n (%)
Group HCV Rx
18 cases
n (%)
Group  HCV
untreated
31  cases
n  (%)
Marked improvement (>6 IPU) – – 2 (11.2) 4 (12.9) – –
Moderate improvement (2–6 IPU) – – 1 (5.6) 5 (16.2) 2 (11.2) 2 (6.4)
Unchanged (<2 IPU to <2 DPU) 16 (88.9) 24 (77.4) 12 (66.7) 14 (45.2) 14 (77.8) 28 (90.3)
Moderate deterioration (2–6 DPU) 2 (11.2) 2 (6.5) 3 (16.7) 7 (22.5) 2 (11.2) 1 (3.3)
Marked deterioration (>6 DPU) – 5 (16.1) – 1 (3.2) – –
Table 4 – Correlation between liver ﬁbrosis, necroinﬂammation (HAI) or steatosis scores in the 1st Liver biopsy (LB) and
changes in liver ﬁbrosis in the 2nd LB, expressed as Improvement Progression Unit (IPU) or Deterioration Progression
Unit (DPU) in Group HCV Rx and Group HCV untreated.
Changes in ﬁbrosis in the 2nd LB in Group HCV
Rx,  18 cases
Changes  in ﬁbrosis in the 2nd LB in Group HCV
untreated, 31 cases
Histological
scores
Moderate/marked
improvement
(2 to >6 IPU)
n (%)
Unchanged
(<2  IPU to <2
DPU)
n (%)
Moderate
Deterior.**
(2–6 DPU)
n  (%)
Marked
deterior.
(>6D PU)
n (%)
Moderate/marked
improvement
(2 to >6 IPU)
n (%)
Unchanged
(<2  IPU to <2
DPU)
n (%)
Moderate
Deterior.
(2–6 DPU)
n  (%)
Marked
Deterior.
(>6D PU)
n (%)
Fibrosis
1st LB
0  – – 1 (5.6) – – – – –
1 – 6 (33.4) 1 (5.6) – – 9 (29) 2 (6.5) 5 (16.1)
2 – 3 (16.7) – – – 8 (25.9) – –
3 – 4 (22.8) – – – 1 (3.2) – –
4 3 (16.7) – – – 1 (2.3) – –
5 – – – – 3 (9.7) – –
6 – – – – 2 (6.5) – –
HAI
1st LB
0  – – – – – 1 (3.2) – 1 (3.2)
1–3 – 10 (55.6) – – – 10 (32.3) 3 (9.7) –
4–8 – 4 (22.3) 2 (11.2) – – 9 (29) 3 (9.7) –
9–12 – – – – – 1 (3.2) – –
13–18 – 2 (11.2) – – – 3 (9.7) – –
Steatosis
1st LB
0  – 6 (33.4) – – – 7 (22.6) – –
1 – 3 (16.7) 1 (5.6) – – 6 (19.4) 5 (16.1) –
2 – – – – – 1 (3.2) – –
3 – 5 (27.8) – – – 5 (16.1) – –
– 4 – 2 (11.2) 1 (5.6) 
denied by other investigators.25 Liver steatosis was consid-
ered  a risk factor for developing a more  severe ﬁbrosis in
HIV/HCV  coinfected patients,22,24,26 a datum not conﬁrmed
by other authors6,27 and by the results of the present study
showing in both groups no correlation between the initial
score  of liver steatosis and changes in ﬁbrosis in the 2nd
LB.
Indeed,  no correlation was  also found in both groups of
patients  between the score of necro-inﬂammation in the 1st
LB  and the progression of this lesion, liver ﬁbrosis and liver
steatosis  nor between the score of liver ﬁbrosis in the 1st
LB  and the progression of liver ﬁbrosis itself, steatosis and– 5 (16.1) 1 (3.2) 1 (3.2)
necro-inﬂammation in the 2nd one. These data allow to con-
cluding  that the evolution of liver ﬁbrosis, necro-inﬂammation
and steatosis in patients with HIV/HCV coinfection may  hardly
be  predicted by the initial degree of these histological lesions.
Concluding, the data of the present study indicate that
the  progression to a more  severe stage of liver ﬁbrosis or to
cirrhosis  observed in nearly a quarter of untreated patients
over  a period of four years may  possibly be prevented by  an
anti-HCV  treatment. This strongly suggests to consider early
anti-HCV  treatment, possibly including a newly  developed
protease inhibitor, all HIV/HCV coinfected patients who  can
reasonably  tolerate therapy.
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